Literature DB >> 10860943

Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.

D P Williams1, M Pirmohamed, D J Naisbitt, J P Uetrecht, B K Park.   

Abstract

Clozapine, an atypical antipsychotic used in the treatment of refractory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively. Clozapine undergoes bioactivation to a chemically reactive nitrenium ion, which has been shown to cause neutrophil cytotoxicity. To define further the mechanism of cell death, we have investigated the toxicity of clozapine, its stable metabolites, and its chemically reactive nitrenium ion to neutrophils and lymphocytes. Clozapine was able to induce neutrophil apoptosis at therapeutic concentrations (1-3 microM) only when it was bioactivated to the nitrenium ion. The parent drug caused apoptosis at supratherapeutic concentrations (100-300 microM) only. Neutrophil apoptosis induced by the nitrenium ion, but not by the parent drug itself, was inhibited by antioxidants and genistein and was accompanied by cell surface haptenation (assessed by flow cytometry) and glutathione depletion. Dual-color flow cytometry showed that neutrophils that were haptenated were the same cells that underwent apoptosis. No apoptosis of lymphocytes was evident with the nitrenium ion or the parent drug, despite the fact that the former caused cell surface haptenation, glutathione depletion, and loss of membrane integrity. Demethylclozapine, the major stable metabolite in vivo, showed a profile that was similar to, although less marked than that observed with clozapine. N-oxidation of clozapine or replacement of the nitrogen (at position 5) by sulfur produced compounds that were entirely nontoxic to neutrophils. In conclusion, the findings of the study expand on potential mechanisms of clozapine-induced cytotoxicity, which may be of relevance to the major forms of toxicity encountered in patients taking this drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860943     DOI: 10.1124/mol.58.1.207

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

Review 2.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.

Authors:  Brian R Curtis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

5.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

Review 6.  Immunopharmacology of hypersensitivity reactions to drugs.

Authors:  Dean J Naisbitt; Munir Pirmohamed; B Kevin Park
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

7.  Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study.

Authors:  Lun Yang; Kejian Wang; Jian Chen; Anil G Jegga; Heng Luo; Leming Shi; Chunling Wan; Xizhi Guo; Shengying Qin; Guang He; Guoyin Feng; Lin He
Journal:  PLoS Comput Biol       Date:  2011-03-31       Impact factor: 4.475

8.  Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia.

Authors:  Arsen Arakelyan; Roksana Zakharyan; Aren Khoyetsyan; David Poghosyan; Rouben Aroutiounian; Frantisek Mrazek; Martin Petrek; Anna Boyajyan
Journal:  BMC Clin Pathol       Date:  2011-08-25

9.  Late onset clozapine induced agranulocytosis.

Authors:  Rajmohan Velayudhan; Sushil Kakkan
Journal:  Indian J Psychol Med       Date:  2014-10

10.  Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase.

Authors:  Lulu Jiang; Xuefei Wu; Shuo Wang; Shih-Heng Chen; Hui Zhou; Belinda Wilson; Chun-Yang Jin; Ru-Band Lu; Keqin Xie; Qingshan Wang; Jau-Shyong Hong
Journal:  J Neuroinflammation       Date:  2016-05-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.